Search
dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR)
Indications:
- hepatitis C infection genotype 1
Contraindications:
- concurrent use of ethinyl estradiol
- moderate to severe hepatic impairment (Child-Pugh class B & C)
Adverse effects:
- fatigue
- asthenia
- nausea,
- insomnia
- pruritus & other skin reactions
- hepatoxicity [3]
- elevated serum transaminases (5-fold elevation in 1%)
- reactivation of hepatitis B in patients with current or previous hepatitis B infection [2]
- 24% of patients with chronic hepatitis B [3]
- 1.4% with resolved hepatitis B infection [3]
Drug interactions:
- contraceptives containing ethinyl estradiol increase likelihood of increased serum transaminases
- proton pump inibitors have no effect on efficacy
Notes:
- manufacturer: Abbvie
Interactions
drug interactions
Related
ombitasvir/paritaprevir/ritonavir (Viekira, Technivie)
General
antiviral combination
References
- FDA Approves Single-Tablet Viekira XR for Hepatitis C.
Medscape. Jul 26, 2016.
http://www.medscape.com/viewarticle/866680
- FDA Drug Safety Communication: Oct 4, 2016
FDA warns about the risk of hepatitis B reactivating in some
patients treated with direct-acting antivirals for hepatitis C.
http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
- Mucke MM, Backus LI, Mucke VT et al
Hepatitis B virus reactivation during direct-acting antiviral
therapy for hepatitis C: a systematic review and meta-analysis.
Lancet Gastroenterology & Hepatology. Jan 19, 2018
PMID: 29371017
http://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30002-5/fulltext
Components
dasabuvir
ombitasvir
paritaprevir
ritonavir (Norvir, RTV)